Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL289271 | 0.98 | OPRM1 (0.44) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL20941858 | 0.92 | OPRM1 (0.41) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL17101303 | 0.90 | OPRM1 (0.40) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL20669116 | 0.90 | OPRM1 (0.38) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL4472210 | 0.89 | OPRM1 (0.40) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL26683264 | 0.87 | OPRM1 (0.39) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL16190003 | 0.85 | — | — | |
| SCHEMBL20758523 | 0.84 | CRBN (0.38) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL1133336 | 0.84 | NEK2 (0.39) | OPRM1OPRL1SMN1; SMN2NEK2CRBN | |
| SCHEMBL31580458 | 0.84 | OPRM1 (0.42) | OPRM1OPRL1SMN1; SMN2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119604494-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2024013209-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-01-18 | — | — | WO | claimed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| CN-115151534-A | Inhibitors of interleukin-1 receptor-related kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| CN-113135921-B | Dihydropyrimidine-spiro derivative and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| EP-3911640-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| EP-3911648-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2021-11-24 | — | — | EP | claimed |
| CN-113574055-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-14 | — | — | US | claimed |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | claimed |
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | claimed |
| WO-2005075484-A2 | CHEMOKINE CCR5 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | claimed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | claimed |
| EP-0412821-B1 | 1-oxa-2-oxo-3,8-diazaspiro[4,5]decane derivatives, pharmaceutical compositions containing them and processes for preparing them | RICHTER GEDEON VEGYESZET (HU) | 1994-11-09 | — | — | EP | claimed |
| EP-0414422-B1 | 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZET (HU) | 1994-04-06 | — | — | EP | claimed |
| EP-0414421-B1 | 1-Oxa-2-oxo-8-azaspiro[4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZET (HU) | 1994-04-06 | — | — | EP | claimed |
| EP-0414421-A2 | 1-Oxa-2-oxo-8-azaspiro[4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-27 | — | — | EP | claimed |
| EP-0412821-A2 | 1-oxa-2-oxo-3,8-diazaspiro[4,5]decane derivatives, pharmaceutical compositions containing them and processes for preparing them | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256108-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | OPRM1 87/4885OPRL1 78/4885SMN1; SMN2 3011/4885 |
| US-20060205710-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | OPRM1 87/4885OPRL1 78/4885SMN1; SMN2 3011/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | OPRM1 87/4885OPRL1 78/4885SMN1; SMN2 3011/4885 |
| US-20060199794-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | OPRM1 87/4885OPRL1 78/4885SMN1; SMN2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.